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BACKGROUND: Blood lipid levels as part of the metabolic syndrome are thought to be linked to cancer risk. Few epidemiological studies
have addressed the association between serum triglyceride (STG) concentrations and cancer risk.
METHODS: Serum triglyceride concentrations were collected in a health investigation (1988–2003). The analyses included 156153
subjects (71693 men and 84460 women), with 5079 incident cancers in men and 4738 cancers in women, and an average of 10.6
years of follow-up. All malignancies were ascertained from the population cancer registry. Multivariate Cox proportional hazard
models stratified by age and sex were used to determine adjusted cancer risk estimates and 95% confidence interval (95% CI).
RESULTS: In men and women combined, higher STG concentrations were associated with increased risk of lung (4th vs 1st quartile: HR,
1.94; 95% CI, 1.47–2.54), rectal (HR, 1.56; 95% CI, 1.00–2.44), and thyroid cancer (HR, 1.96; 95% CI, 1.00–3.84). Serum triglyceride
concentrations were inversely associated with non-Hodgkin’s lymphoma. In men, STG concentrations were inversely associated with
prostate cancer and positively with renal cancer. In women, STG concentrations were positively associated with gynaecological
cancers. Stratification by BMI revealed a higher risk of gynaecological cancers in overweight than in normal weight women. No other
associations were found.
CONCLUSIONS: Our findings support the hypothesis that STG concentrations are involved in the pathogenesis of lung, rectal, thyroid,
prostate, and gynaecological cancers.
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Obesity has been identified as a major risk factor for such cancer
sites as colon, renal, breast, and endometrium (Bianchini et al,
2002; Calle and Kaaks, 2004; Rapp et al, 2005), whereas
hypertriglyceridemia is relevant to obesity and insulin resistance
(Despres and Lemieux, 2006). Dietary fat intake is a well-
established risk factor in cardiovascular diseases (CVDs), in which
much investigation has involved serum triglyceride (STG)
concentrations (Sarwar et al, 2007). The combination of hyper-
triglyceridemia and elevated waist circumference has been
identified as a phenotype for higher risk of CVD (Kahn and
Valdez, 2003). Usually, fasting triglyceride concentrations are
measured, as they are associated with increased mortality and CVD
risk (Brunzell, 2007). However, there is uncertainty with regard to
the impact of STG concentrations on risk of CVD (Gotto, 1998 and
also with regard to whether fasting level influences the relationship
(Langsted et al, 2008). Beyond lipid metabolism there is evidence
that hypertriglyceridemia is associated with frequent infections
and inflammation (Khovidhunkit et al, 2004; Esteve et al, 2005).
A few cohort studies have investigated high STG concentrations
as a part of the metabolic syndrome (Tulinius et al, 1997) in
relation to risk of colon (Saydah et al, 2003; Ahmed et al, 2006,
Tande et al, 2006), breast (Vatten and Foss, 1990; Furberg et al,
2004), and cervix cancers (Cust et al, 2007). A cohort study among
Icelanders (Tulinius et al, 1997) revealed associations between high
STG levels and colorectal cancers in both sexes, and also with
thyroid cancer in men, as well as with cervix, endometrial, and
bladder cancer in women (Tulinius et al, 1997).
We therefore investigated the associations between fasting STG
concentrations and cancer risk in a large prospective cohort study.
METHODS
Study population
Details of the Vorarlberg Health Monitoring and Promotion
Program (VHM&PP) in Vorarlberg, the most western region
in Austria, are provided elsewhere (Rapp et al, 2005). In brief, the
Agency of Social and Preventive Medicine annually offered to all
adults living in Vorarlberg a screening examination that includes a
physical examination, a blood test, and a consultation with a
doctor. By 2005, B56% of all Vorarlberg residents underwent at
least one examination in this voluntary screening programme.
Between 1988 and 2003, over 156000 adult Vorarlberg residents
were enrolled in the cohort after signing an informed consent form
to store and process personal data and biological samples.
For the current analysis, we used a data set with complete data
on STG and covariates at baseline. Participants with follow-up
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melanoma skin cancer), were excluded before enrolment or within
1 year after enrolment (n¼2149).
Two central laboratories, with regular internal and external
quality tests, determined STG concentrations on fasting blood
samples. Within 60–240min of venous blood sample collection
from a cubital vein, serum was obtained by centrifugation for
15min at 4000r.p.m. Subsequently, STG concentrations were
measured at 371C and were expressed as mg per 100ml. To check
calibration, three daily control samples were included. If average
values of control samples of each run were not within 3% of the
true value, the run was repeated. Day-by-day variation had to be
within 5%. Study participants are classified according to the
quartiles of STG concentrations with the following cutoff values:
p83, 84–119, 120–179, and X180mg100ml for men and p69,
70–94, 95–133, and X134mg100ml for women. Participants in
the 1st quartile were used as reference category.
Measurements of height, weight, blood pressure, total choles-
terol, blood glucose, and gamma-glutamyltransferase (GGT)
were obtained routinely for each participant. BMI was calculated
by height and weight at baseline and was categorised on the basis
of clinical guidelines (o25kgm
–2,2 5t oo30kgm
 2,
X30.0kgm
 2) (World Health Organisation, 1998). Smoking
status was classified as current, former, or non-smokers.
Participants who never smoked could not be distinguished
from those who did not respond to questions with regard to
smoking at baseline, but baseline smoking status was verified
for 470% of study participants on the basis of information
provided at subsequent examinations. As a proxy for socio-
economic position, the occupational group (blue collar,
white collar, or self-employed) was determined by the participant’s
insurance number. Retired participants were classified according
to their former occupation, and housewives on the basis of the job
of their spouse.
As described previously in detail (Rapp et al, 2005), cancer cases
were identified by record linkage with the Vorarlberg cancer
registry, which has been accepted for IARC publication since 1993
(Parkin DM et al, 2003) and has high completeness of ascertain-
ment (Oberaigner W, 2006). In the Vorarlberg cancer registry,
nearly all cancers (96.7%) were histologically verified and the
Death-certificate-only (DCO) rate meets international quality
criteria (5% for both sexes in 1998–2002). Cohort data were
linked to the Vorarlberg Death Index to identify deaths and to
calculate person-years. The current analysis makes use of the data
set updated at the end of 2003. The average follow-up time was 10.6
(s.d. 4.5) years. The 10th Revision of the International Statistical
Classification of Diseases, Injuries and Causes of Death (ICD) was
used to code the cancers (World Health Organization, 2008).
Statistical analysis
The analytical cohort comprised 156153 subjects (71693 men and
84460 women). Partial correlation coefficients were calculated to
examine the relationship between STG and other clinical
parameters. Cox proportional hazard models were used to
compute hazard ratios (HRs) and 95% confidence intervals (CIs)
for quartiles relative to the reference group (1st quartile of STG
level). Models were adjusted for serum concentrations of glucose
(mg per 100ml, continuous)(Rapp et al, 2006), total cholesterol
(mg per 100ml, continuous) (Ulmer et al, 2004; Strasak et al,
2009), GGT (Ul
–1, continuous) (Strasak et al, 2008a,b), body mass
index (BMI, kgm
 2, continuous) (Rapp et al, 2005), occupational
status, and smoking status (both in classes). Continuous risk
estimates are presented for an increase in exposures of one unit
log-transformed STG concentration. To test the overall signifi-
cance of exposure, P-values for Wald w
2 statistics are shown. As no
obvious sex differences between the estimates emerged, models
were calculated for the sexes combined. All P-values are two-sided
and all calculations were carried out with SAS statistical software
package SAS release 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
During follow-up, 5079 incident invasive cancer cases among men
and 4738 incident invasive cancer cases among women were
identified (Table 1). Correlations between BMI, age, and serum
concentrations of STG, total cholesterol, glucose, and GGT are
shown in Table 2. STG was weakly associated with serum glucose
concentrations and moderately associated with BMI, total choles-
terol, and GGT concentrations.
Table 3 shows the hazard ratios for cancer type by STG
concentrations in the VHM&PP cohorts. Compared with the 1st
quartile, high STG concentrations (4th quartile) were associated
with increased risk of lung (HR, 1.94; 95% CI, 1.47–2.54), rectal
(HR, 1.56; 95% CI, 1.00–2.44), and thyroid cancer (HR, 1.96; 95%
CI, 1.00–3.84). High STG concentrations were inversely associated
with non-Hodgkin’s lymphoma. Prostate cancer was inversely
associated with STG concentrations (per log-unit HR, 0.80; 95% CI,
0.72–0.90) and was positively associated with incidence of kidney
cancer in men (data not shown). High STG concentrations were
associated with higher overall cancer risk (4th vs 1st quartile: HR,
1.19; 95% CI, 1.05–1.33) and with risk of gynaecological cancers
(endometrium, ovar, cervix) (4th vs 1st quartile: HR, 1.62; 95% CI,
1.13–2.33).
Table 1 Characteristics of the study population (N¼156153) by quartile of serum triglyceride (STG) concentration
All 1st quartile 2nd quartile 3rd quartile 4th quartile
Triglycerides (mg100ml
 1), median (Q1, Q3) 104.0 (74.0, 152.0) 61.0 (52.0, 68.0) 88.0 (81.0, 96.0) 124.0 (114.0, 137.0) 207.0 (175.0, 269.0)
Total cholesterol (mg100ml
 1), mean (s.d.) 213.7 (45.8) 188.8 (36.3) 206.1 (39.2) 220.0 (41.7) 240.9 (48.5)
Glucose (mg100ml
 1), mean (s.d.) 87.2 (22.6) 83.7 (16.3) 85.0 (20.0) 87.2 (21.0) 93.0 (31.2)
Gamma-glutamyltransferase (GGT) (Ul
 1), median (Q1, Q3) 12.0 (8.0, 18.0) 9.0 (7.0, 13.0) 11.0 (8.0, 15.0) 12.0 (9.0, 19.0) 18.0 (12.0, 29.0)
Age (years), mean (s.d.) 41.8 (15.1) 37.2 (13.0) 40.8 (15.1) 43.4 (15.9) 50.0 (14.9)
BMI (kgm
 2), mean (s.d.) 24.7 (4.2) 22.9 (3.4) 24.1 (3.9) 25.2 (4.3) 30.0 (4.3)
Current smokers (%) 25.2 20.4 23.7 26.1 30.8
Occupational status: white collar (%) 54.3 58.3 56.1 53.3 49.3
Table 2 Correlation of serum triglyceride (STG) concentrations with
other clinical measures in the study population
Covariates
Correlation
coefficients
a P-value
BMI (kgm
 2) 0.30 o0.001
Total cholesterol (mg100ml
 1) 0.41 o0.001
Glucose (mg100ml
 1) 0.14 o0.001
Gamma-glutamyltransferase (GGT) (Ul
 1) 0.32 o0.001
aAge- and sex- adjusted partial correlation coefficients, STG, and GGT were log
transformed.
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stratified by BMI. These did not reveal differential associations
of STG levels with cancer overall, or with lung and colon cancer
risk; however, the risk of gynaecological cancers was higher in
overweight than in normal weight women. When data were stra-
tified by smoking status (data not shown), no differential estimates
emerged for overall and gynaecological cancers, but a somewhat
higher risk of rectal cancer was found in current smokers (N¼50
cases; per log-unit HR, 1.73; 95% CI, 1.02–2.92) than in non-
smokers (N¼177 cases; per log-unit HR, 1.11; 95% CI, 0.79–1.56),
and a higher risk of lung cancer was found in non-smokers
(N¼222 cases; per log-unit HR, 1.57; 95% CI, 1.19–2.06) than in
smokers (N¼334 cases; per log-unit HR, 1.13; 95% CI, 0.91–1.39).
However, no significant effect modification by BMI and smoking
status was found. Stratification by GGT levels (p30 and
430Ul
 1) revealed differential relationships between STG and
overall cancer risk and lung cancer (data not shown).
DISCUSSION
In this large-scale cohort study, high STG concentrations were
associated with higher overall cancer risk in women, but not in men.
In men and women combined, STG concentrations were related to
high risk of lung, thyroid, and rectal cancer. In men, STG
concentrations were associated inversely with prostate cancer, and
in women they were associated positively with gynaecological cancers.
Our findings regarding lung, rectal, and gynaecological cancers are
consistent with data using dietary fat intake levels as exposure
variable (Kushi and Giovannucci, 2002; Genkinger et al, 2006).
Our observation of a positive association between STG levels
and rectal cancer is in line with previous findings in a cohort study
among Icelanders (Tulinius et al, 1997). Further evidence for a
relationship with STG comes from case–control studies on
colorectal adenoma (Kono et al, 1990; Bird et al, 1996; Otani
et al, 2006; Tabuchi et al, 2006), carcinoma in situ (Yamada et al,
1998), and from an in-vitro study (Tabuchi et al, 2008). It has been
suggested that total cholesterol, STG, and plasma glucose are
positively associated with colorectal cancer risk (Yamada et al,
1998). In our study, the association occurred adjusted for plasma
glucose and total cholesterol concentrations. In men and women
combined, we observed an association between STG concentration
and rectal cancer risk, whereas no association was found for colon
cancer, neither was any association found in sex-stratified
analyses. Consistent with a study among Japanese-American men
(Tsushima et al, 2005) and US prospective studies (Saydah et al,
2003; Ahmed et al, 2006), we did not find a relationship with
colorectal cancer.
Our findings of high lung cancer risk among subjects with high
STG concentrations are unique. In one study, an association
between total cholesterol and lung cancer risk has been observed,
suggesting a relationship between lipid metabolism and lung
cancer risk (Hinds et al, 1983). In the Carotene and Retinol
Efficacy Trial (CARET), among the participants receiving
b-carotene and retinol, higher serum triglyceride concentrations
were observed (Cartmel et al, 2005), suggesting a relationship
between STG and lung cancer risk. As smoking is associated with
higher STG concentrations (Brunzell, 2007), residual confounding
due to smoking may contribute to the association between STG
concentrations and lung cancer risk. In our study, however, the
association persisted when the data set was limited to non-
smokers, suggesting that factors other than smoking status may
contribute to the observed association. The limited differentiation
between missing smoking data and non-smoking status may have
resulted in misclassification of smoking status. However, smoking
information from follow-up visits for most of the participants was
used to complement the baseline smoking status.
The positive association with thyroid cancer risk is in line
with findings in a cohort study (Tulinius et al, 1997). It may be
relevant that BMI was positively associated with thyroid cancer
(Renehan et al, 2008).
In our study, STG concentrations were inversely associated with
prostate cancer risk, in contrast to the reverse findings in a case–
control study (Wuermli et al, 2005). However, in this clinical-based
study, prostate cancers were compared with benign prostate
hyperplasia, in which STG levels were lower than those in cancer
cases. In large cohort studies in Norway and the United States, no
association between STG and prostate cancer risk was found (Lund
Table 3 Hazard ratios (HR with 95% CI) and numbers of cases for cancers by site and STG quartiles
a
Cancer site of
both sexes
ICD-10 codes
Total no.
of cases
1st
quartile
2nd
quartile
3rd
quartile
4th
quartile
Total per log-
unit increase
P-value for log
unit increase
Thyroid C73 (101) (16) 1.00 (25) 1.55 (0.82–3.00) (30) 1.84 (0.97–3.48) (30) 1.96 (1.00–3.84) 1.16 (0.76–1.76) 0.492
Plasmacytoma C90 (73) (7) 1.00 (19) 1.88 (0.74–4.78) (16) 1.37 (0.52–3.59) (31) 2.11 (0.82–5.43) 1.39 (0.84–2.31) 0.204
NHL C82–C85 (219) (42) 1.00 (61) 0.99 (0.66–1.49) (54) 0.71 (0.46–1.07) (62) 0.68 (0.43–1.07) 0.71 (0.52–0.97) 0.033
Stomach C16 (315) (41) (80) 1.32 (0.90–1.95) (83) 1.22 (0.83–1.82) (111) 1.45 (0.97–2.17) 1.17 (0.92–1.49) 0.208
Pancreatic C25 (162) (24) 1.00 (35) 0.99 (0.58–1.69) (39) 0.86 (0.50–1.47) (64) 1.19 (0.70–2.05) 1.25 (0.90–1.75) 0.188
Colon C18 (600) (81) 1.00 (122) 0.93 (0.70–1.23) (175) 1.05 (0.80–1.39) (222) 1.08 (0.81–1.43) 1.06 (0.88–1.26) 0.547
Rectal C19/20 (273) (32) 1.00 (69) 1.47 (0.95–2.26) (69) 1.25 (0.81–1.94 (103) 1.56 (1.00–2.44) 1.20 (0.92–1.55) 0.184
Bladder C67 (158) (24) 1.00 (36) 1.50 (0.48–4.71) (59) 0.73 (0.22–2.46) (39) 1.42 (0.45–4.43) 1.03 (0.98–1.09) 0.218
Kidney C64 (216) (35) 1.00 (40) 0.81 90.51–1.280 (51) 0.88 (0.57–1.38) (90) 1.27 (0.81–1.97) 1.27 (0.95–1.69) 0.105
Lung C34 (650) (86) 1.00 (128) (1.12 0.85–1.48) (179) (1.43 1.09–1.87) (257) (1.94 1.47–2.54) 1.50 (1.28–1.75) o0.0001
Men
Prostate C61 (1484) (304) 1.00 (397) 0.94 (0.80–1.09) (470) 0.87 (0.75–1.02) (353) 0.67 (0.56–0.80) 0.80 (0.72–0.90) o0.001
Women
Breast C50 p50
years
(510) (127) 1.00 (157) 1.25 (0.98–1.59) (136) 1.23 (0.95–1.59) (90) 0.95 (0.70–1.28) 0.92 (0.74–1.15) 0.455
Breast 450 years (694) (75) 1.00 (135) 0.93 (0.70- 1.24) 200 1.00 (0.76–1.32) 284 1.05 (0.79–1.39) 1.09 (0.91–1.30) 0.352
Cervical C53 (70) (12) 1.00 (17) 1.48 (0.69–3.19) (18) 1.52 (0.70–3.34) (23) 2.00 (0.89- 4.50) 1.74 (1.03–2.95 0.038
Endometrium C54 (236) (22) 1.00 (50) 1.38 (0.83–2.30) (54) 1.11 (0.66–1.86) (110) 1.61 (0.97–2.67) 1.22 (0.90–1.65) 0.206
Ovarian C56 (123) (16) (29) 1.57 (0.81–3.04) (39) 1.75 (0.91–3.37) (39) 1.43 (0.71–2.85) 1.13 (0.74–1.74) 0.576
Gynaecological
(C53, 54, 56)
(429) (50) 1.00 (96) 1.45 (1.01- 2.07) (111) 1.35 (0.94–1.93) (172) 1.62 (1.13–2.33) 1.26 (1.01–1.58) 0.042
aAdjusted for BMI (kgm
 2, continuous), GGT (continuous), serum glucose (continuous), total cholesterol concentration (continuous), smoking status, and occupational status.
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antigen contributes to heterogeneity of phenotype (Etzioni et al,
2002), which may have distorted the relationship with STG. In
addition, an inverse relationship for NHL was observed in our
study. Previous reports on cholesterol indicted that reverse
causation may substantially contribute to the risk-lowering effect
of high blood lipids (Rose and Shipley, 1980; Lim et al, 2007;
Strasak et al, 2009).
Our observation that STG concentrations were positively
associated with kidney cancer incidence in men (data not shown)
contrasts with a recently published meta-analysis on BMI and
renal cancer risk (Renehan et al, 2008). However, in our study,
after adjusting for diastolic blood pressure, an established risk
factor for renal cancer (per log-unit HR, 1.26; 95% CI, 0.95–1.68),
the association was no longer statistically significant. For men and
women combined, we found no statistically significant association
between STG and kidney cancer risk.
Our observation of a positive association of STG concentrations
with risk of gynaecological cancers (cervix, ovary, endometrial) is
consistent with other studies (Tulinius et al, 1997; Cust et al, 2007).
In one study, increasing triglyceride and glucose concentrations
were associated with increased endometrial cancer risk (Cust et al,
2007). Our findings on cervical cancer are in line with those in a
cohort study (Tulinius et al, 1997). For breast cancer, inconsistent
results have been reported from a nested case–control study
(Agnoli et al, 2009) and from cohort studies (Vatten and Foss,
1990; Furberg et al, 2004).
These associations with gynaecological cancer raise a question
with regard to the involvement of oestrogens, which are considered
to stimulate hepatic triglyceride secretion (Sattler et al, 2005), as
confirmed by studies on hormone replacement therapy (Rossouw
et al, 2008; Sowers et al, 2008).
High STG concentrations may reflect other metabolic aspects that
are procarcinogenic (McKeown-Eyssen, 1994). Associations between
STG and plasma glucose levels are well established and hypergly-
caemia is a risk factor for several cancers (Ashley and Kannel, 1974).
In our study, however, we used fasting STG levels and adjusted for
plasma glucose levels to control for confounding by glucose levels.
Inflammation is another potential mechanism by which hypertrigly-
ceridemia is associated with cancer risk (Esteve et al, 2005; Kundu
and Surh, 2008). STG concentrations may be linked to colorectal
cancer risk by bile acid excretion, circulation hormones, or energy
supply to neoplastic cells (McKeown-Eyssen, 1994).
A limitation of our study is the lack of information on
such potential risk factors as alcohol consumption and physical
activity. However, the results of our multivariate models adjusted
for GGT concentrations may be considered as a proxy variable
for alcohol intake (Whitehead et al, 1978). In addition, no
information on medication history (for example, on lipid-lowering
drugs or hormones) was available, which may have affected the
associations observed. Among women, the effect of STG may be
overestimated because of residual confounding by exogenous
hormones, whereas for lipid-lowering medications, the opposite
could be relevant.
Undocumented measurement variation in STG concentrations
during the study period may also have affected our results, but we
assume that these were minor, as we used fasting STG levels. The
strengths of our study are large sample size, prospective design,
length of follow-up, and standardised examinations by trained
physicians. It is relevant that the study population is relatively
young and healthy.
Overall, STG concentrations were positively associated with the
risk of lung, thyroid, and rectal cancers, but inversely with NHL
risk. Prostate cancer risk was inversely associated with STG
concentrations, whereas positive associations were found with
renal cancer among men and with gynaecological cancers among
women. Our results suggest that STG concentrations are involved
in the pathogenesis of several cancer sites.
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